GlassScriptPhysician profile
Preston D Thomas
NPI 1427018571
$1,528.28
in general payments reported to CMS, 2019-2025
19 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $81.32 · 2022: $208 · 2023: $380 · 2024: $231 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $504.67 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $437.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $130.13 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $85.95 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Supernus Pharmaceuticals, INC. | $77.60 | 2019-2022 | |
| Abbvie INC. | $45.19 | 2023 | Linzess, Creon, Vraylar |
| Pfizer INC. | $39.11 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $25.63 | 2024 | Rexulti |
| Eisai INC. | $24.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.50 | 2023 | |
| Abbott Laboratories | $21.55 | 2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $17.47 | 2019 | |
| Astellas Pharma US INC | $16.67 | 2022 | |
| Pulmonx Corporation | $16.67 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $15.69 | 2023 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $14.86 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $13.84 | 2019 | |
| Allergan, INC. | $12.52 | 2019 | |
| Kvk-Tech, INC. | $5.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preston Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.